Is Atai Beckley Inc. (ATAI) a Buy, Sell, or Hold?
NASDAQ : ATAI
Atai Beckley Inc.
$7.17 USD
-$0.01 (-0.14%)
- Volume
- 9.6M
- Average Volume
- 10.69M
- Market Capitalization
- $2.65B
- P/E Ratio
- -2.39
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $7.22
- Year Low
- $3.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.02
Company Overview
NASDAQ
Srinivas G. Rao
Biotechnology
Healthcare
ATAI
99
US
USD
Liquidity Metrics
0.01
10.02
10.02
1.73
0.00
Sales & Valuation
$4.09M
760.48
8.18
-22.64
-0.52
Profitability
-$2.91
-$660.05M
-19019.44%
-19018.90%
-366.49%
-250.46%
P/E Metrics
-2.39
0.01
0.01
Analyst Price Target & Rating
$7.50
$12.00
$7.45
2/5
7 Analysts
-4.40%
Financial Health Scores
9.54
4/9
$225.1M
$264.88M
$66.1M
-$663.12M
Key Metrics (TTM)
$2.62B
749.76
-3.95
10.02
-366.49%
-53.11%
-40.79%
-4.41%
-4739 days
Company Executives
| Name | Title |
|---|---|
| Srinivas G. Rao | Co-Founder, Chief Executive Officer & Executive Director |
| Anne Johnson | Chief Accounting Officer |
| Christian Angermayer | Co-Founder & Chairman of the Board |
| Kavita Panke | Senior Vice President of New Product, Planning & Commercial |
| Robert Conley | Chief Research & Development Officer |
| Gerd G. Kochendoerfer | Chief Operating Officer |
| Michael Eric Faerm | Chief Financial Officer |
| Glenn Short | Chief Scientific Officer |
| Jason Awe | Vice President of Investor Relations |
| Kevin Craig | Chief Medical Officer |
| Ryan Barrett | Chief Legal & Business Officer |
Poll Results
No votes yet today — be the first to share your view!
About Atai Beckley Inc. (NASDAQ:ATAI) Stock
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address ... major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.
2026-07-23 08:45:00
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
2026-07-22 10:56:15
The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
2026-07-21 14:50:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-07-17 14:57:00
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AtaiBeckley Inc. (NasdaqGM: ATAI) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of AtaiBeckley will receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments u.
2026-07-17 13:18:32
Lulu's Fashion Lounge Holdings (NASDAQ:LVLU) retained Solomon Partners as its financial advisor and Willkie Farr & Gallagher LLP as its legal advisor as the company evaluates strategic alternatives to maximize shareholder value. Alternatives may include a potential transaction or continued execution of Lulu's standalone strategic plan.
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
2026-07-17 12:36:15
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
2026-07-17 08:50:00
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company’s...
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
2026-07-17 08:38:23
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly, values AtaiBeckley at $6.75 per share in cash, or about $2.8 billion in equity, plus a contingent value right of up to $2.50 per share, worth roughly $1 billion if certain milestones are achieved.
Frequently Asked Questions
-
What is the current Atai Beckley Inc. (ATAI) stock price?
-
Atai Beckley Inc.(NASDAQ:ATAI) stock price is $7.17 in the last trading session. During the trading session, ATAI stock reached the peak price of $7.22 while $3.06 was the lowest point it dropped to. The percentage change in ATAI stock occurred in the recent session was --0.14% while the dollar amount for the price change in ATAI stock was -$0.01.
-
ATAI's industry and sector of operation?
-
The NASDAQ listed ATAI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATAI?
-
Srinivas G. Rao | Co-Founder, Chief Executive Officer & Executive Director
Anne Johnson | Chief Accounting Officer
Christian Angermayer | Co-Founder & Chairman of the Board
Kavita Panke | Senior Vice President of New Product, Planning & Commercial
Robert Conley | Chief Research & Development Officer -
How many employees does ATAI have?
-
Number of ATAI employees currently stands at 99. ATAI operates from 250 West 34th Street, New York, NY 10119, US.
-
Link for ATAI official website?
-
Official Website of ATAI is: https://www.ataibeckley.com
-
How do I contact ATAI?
-
ATAI could be contacted at phone #332 282 0507 and can also be accessed through its website. ATAI operates from 250 West 34th Street, New York, NY 10119, US.
-
How many shares of ATAI are traded daily?
-
The average number of ATAI shares traded daily for last 3 months was 10.69M.
-
What is the market cap of ATAI currently?
-
The market value of ATAI currently stands at $2.65B with its latest stock price at $7.17